Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 43 of the 46 references it cites were found in a registry or an index.
Abstract
Background: Individuals with congenital adrenal hyperplasia (CAH) require glucocorticoid therapy to replace cortisol and to control androgen excess. We sought to evaluate the effects of glucocorticoid therapy on cardiovascular and metabolic outcomes in individuals with CAH. Methods: We searched bibliographical databases through January 2016 for studies evaluating cardiovascular risk factors in individuals with CAH treated with glucocorticoids compared with controls without CAH. We used a random-effects model to synthesize quantitative data. Results: We included 20 observational studies (14 longitudinal, six cross-sectional) with a moderate to high risk of bias. The average dose of glucocorticoids (in hydrocortisone equivalents) was 9 to 26.5 mg/m2/d. In the meta-analysis (416 patients), compared with controls without CAH, individuals with CAH had increased systolic blood pressure [weighted mean difference (WMD), 4.44 mm Hg; 95% CI, 3.26 to 5.63 mm Hg], diastolic blood pressure (WMD, 2.35 mm Hg; 95% CI, 0.49 to 4.20 mm Hg), homeostatic model assessment of insulin resistance (WMD, 0.49; 95% CI, 0.02 to 0.96), and carotid intima thickness (WMD, 0.08 mm; 95% CI, 0.01 to 0.15 mm). No statistically significant differences were noted in fasting blood glucose, insulin level, glucose, or insulin level after 2-hour glucose load or serum lipids. Data on cardiac events were sparse, and most of the literature focused on surrogate outcomes. Conclusion: Individuals with CAH demonstrate a high prevalence of cardiovascular and metabolic risk factors. The current evidence relies on surrogate outcomes. Long-term prospective studies are warranted to assess strategies for reducing cardiovascular risk in individuals with CAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A meta-analysis of 20 studies of CAH found an increased risk of insulin resistance, elevated blood pressure and carotid intima thickness, although the quality of evidence was low82.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the non-obese patients were similarly affected by hypertension and diabetes as the entire CAH cohort.”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [671]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Obesity was consistently increased in all subgroups while diabetes was increased in females, SV and NC phenotypes and those above 40 years of age.”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [671]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of overweight and obesity are greater in adults with CAH in the UK (360) and Sweden (671) but similar to the general population in the US (217) and France (626,672).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [671]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In another new meta-analysis, investigators found no direct well-controlled evidence of cardiovascular or metabolic morbidity and mortality associated with CAH.”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [41]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We performed a meta-analysis for each of the outcomes of interest using a random-effects model (10).”
(2014) · Medical Entomology and Zoology · Cited by 17,633
Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease
Vasan, R. S., Larson, M. G., Leip, E. P., Evans, J. C., O'Donnell, C. J., Kannel, W. B., & Levy, D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003417 · Cited by 2,082 · cited 1×
“For example, in the Framingham Heart Study cohort, a stepwise increase in cardiovascular event rates was noted in adult men with higher baseline blood pressure categories (35).”
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationBlood Pressure as a Cardiovascular Risk Factor: Prevention and Treatment
Kannel, W. B. (1996) · JAMA · doi:10.1001/jama.1996.03530440051036 · Cited by 1,230
Blood Pressure, Systolic and Diastolic, and Cardiovascular Risks: US Population Data
Stamler, J. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410050036006 · Cited by 1,015
Cited by
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationCongenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
Congenital adrenal hyperplasia
Auer, M. K., Nordenström, A., Lajic, S., & Reisch, N. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01330-7 · Cited by 215
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
Merke, D. P., Mallappa, A., Arlt, W., Brac de la Perriere, A., Lindén Hirschberg, A., Juul, A., Newell-Price, J., Perry, C. G., Prete, A., Rees, D. A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab051 · Cited by 109
“Management involves balancing glucocorticoid doses to avoid both glucocorticoid deficiency, risking adrenal crisis, and iatrogenic glucocorticoid excess, leading to short stature, obesity, hypertension, osteoporosis, and an adverse metabolic profile (1-3, 5-7).”
BackgroundAl Alawi, A. M., Nordenström, A., & Falhammar, H. (2019) · Endocrine · doi:10.1007/s12020-018-01835-3 · Cited by 77
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
Auchus, R. J., Hamidi, O., Pivonello, R., Bancos, I., Russo, G., Witchel, S. F., Isidori, A. M., Rodien, P., Srirangalingam, U., Kiefer, F. W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404656 · Cited by 79
“5, 23– 25 Consistent Consistent with data from the phase 2 trials, 27,28 crinecerfont markedly lowered androstenedione and 17OHP compared with placebo after the initial 4-week GC stable period.”
Self-citationTorky, A., Sinaii, N., Jha, S., Desai, J., El‐Maouche, D., Mallappa, A., & Merke, D. P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab133 · Cited by 84
“We found higher prevalence of hypertensive BP both in children and adults compared to the US general population, consistent with prior studies (4,29).”
BackgroundResultPaizoni, L., Auer, M. K., Schmidt, H., Hübner, A., Bidlingmaier, M., & Reisch, N. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105540 · Cited by 53
Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia
Prete, A., Auchus, R. J., & Ross, R. J. (2022) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 46
Long-Term Outcomes of Congenital Adrenal Hyperplasia
Nordenström, A., Lajić, S., & Falhammar, H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1528 · Cited by 50
“The difference was less evident in children and adolescents than in adults with CAH [29].”
InfluentialHyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women—What Is the Evidence?
Hirschberg, A. L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad590 · Cited by 46
Tsai, C., Liao, C., Wu, X.-M., Chen, Z., Pan, C., Chang, Y., Lee, B., Shun, C., Wen, W.-F., Chou, C., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1157 · Cited by 37
Improda, N., Barbieri, F., Ciccarelli, G. P., Capalbo, D., & Salerno, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00212 · Cited by 34
Kim, J. H., Choi, S., Lee, Y. A., Lee, J., & Kim, S. G. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1328 · Cited by 33
“A recent meta-analysis supports our explanation, since CAH patients showed higher insulin resistance, but similar glucose and lipid levels compared with controls [12].”
BackgroundResultSarafoglou, K., Merke, D. P., Reisch, N., der Grinten, H. L. C., Falhammar, H., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad134 · Cited by 35
Banker, M. M., Puttabyatappa, M., O’Day, P., Goodrich, J. M., Kelley, A. S., Domino, S. E., Smith, Y. R., Dolinoy, D. C., Song, P. X. ‐., Auchus, R. J., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa909 · Cited by 33
Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision)
Ishii, T., Kashimada, K., Amano, N., Takasawa, K., Nakamura‐Utsunomiya, A., Yatsuga, S., Mukai, T., Ida, S., Isobe, M., Fukushi, M., et al. (2022) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2022-0009 · Cited by 37
Gomes, L. G., Mendonca, B. B., & Bachega, T. A. S. S. (2020) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000545 · Cited by 27
Glucocorticoids are active players and therapeutic targets in atherosclerotic cardiovascular disease
van der Sluis, R. J., & Hoekstra, M. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110728 · Cited by 27
“Given that many of the developmental phenotypes found in CAH patients are secondary to the reduced ability of the adrenals to secrete glucocorticoids and mineralocorticoids, hormone replacement therapy serves as the first line treatment of subjects suffering from CAH.”
InfluentialLong‐term health consequences of congenital adrenal hyperplasia
Pofi, R., Ji, X., Krone, N. P., & Tomlinson, J. (2023) · Clinical Endocrinology · doi:10.1111/cen.14967 · Cited by 30
“Confirming previous reports, 157,163 increased prevalence of IR was also reported in this study.”
Cardiometabolic Aspects of Congenital Adrenal Hyperplasia
Krysiak, R. G., der Grinten, H. L. C., Reisch, N., Touraine, P. A., & Falhammar, H. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae026 · Cited by 26
Delai, A., Gomes, P. M., Foss‐Freitas, M. C., Elías, J., Antonini, S. R. R., de Castro, M., Moreira, A. C., & Mermejo, L. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab767 · Cited by 25
Congenital Adrenal Hyperplasia
Fraga, N. R., Minaeian, N., & Kim, M. S. (2024) · Pediatrics in Review · doi:10.1542/pir.2022-005617 · Cited by 31
Developmental programming of insulin resistance: are androgens the culprits?
Puttabyatappa, M., Sargis, R. M., & Padmanabhan, V. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0044 · Cited by 24
Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia
Barbot, M., Mazzeo, P., Lazzara, M., Ceccato, F., & Scaroni, C. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.934675 · Cited by 28
Vijayan, R., Bhavani, N., Pavithran, P. V., Nair, V., Menon, U. V., Menon, A. S., Abraham, N., Bhadran, K., Narayanan, P., & Kumar, H. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0079 · Cited by 22
de Vries, L., Lebenthal, Y., Phillip, M., Shalitin, S., Tenenbaum, A., & Bello, R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00698 · Cited by 22
Russian clinical practice guidelines «congenital adrenal hyperplasia»
Mokrysheva, N. G., Mel'nichenko, G. A., Adamyan, L. V., Troshina, E. A., Молашенко, Н. В., Игоревна, С. А., Uvarova, E. V., Esayan, E. R. M., Andreeva, E. N., Ужегова, Ж. А., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12787 · Cited by 30
Yang, M., & White, P. C. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae535 · Cited by 20
“A systematic review and meta-analysis (10) suggested that individuals with CAH had higher values for the homeostatic model assessment of insulin resistance than controls, but did not differ in fasting blood glucose, insulin level, glucose or insulin level after a 2-hour glucose load, or serum…”
Insulin Resistance in Congenital Adrenal Hyperplasia is Compensated for by Reduced Insulin Clearance
de Oliveira, D. M., Tura, A., Vasques, A. C. J., Camilo, D. F., Lima, M. M. D. O., de Lemos‐Marini, S. H. V., Gonçalves, E. M., Guerra‐Júnior, G., & Geloneze, B. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab010 · Cited by 18
Components of Metabolic Syndrome in Youth With Classical Congenital Adrenal Hyperplasia
Kim, M. S., Fraga, N. R., Minaeian, N., & Geffner, M. E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.848274 · Cited by 25
“2018 (30) MetaAnalysis Pediatric and Adult CAH patients had increased SBP, DBP, insulin resistance, and cIMT, but no evidence of morbidity or mortality due to cardiac events.”
Backgroundder Grinten, H. L. C., Adriaansen, B. P. H., & Falhammar, H. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae718 · Cited by 19
Animal Foetal Models of Obesity and Diabetes – From Laboratory to Clinical Settings
Grzęda, E., Matuszewska, J., Ziarniak, K., Gertig-Kolasa, A., Krzyśko-Pieczka, I., Skowrońska, B., & Sliwowska, J. H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.785674 · Cited by 20
Cussen, L., McDonnell, T., Miller, C., McIlroy, M., & O’Reilly, M. (2025) · Reproduction · doi:10.1530/rep-25-0102 · Cited by 23
Endocrine Disorders and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
Betlejewska, J., Hubska, J., Roszkowska, Z., Maciejczyk, A., Bachurska, D., Domański, J., Miarka, M., Raszeja‐Wyszomirska, J., Bobrowicz, M., & Ambroziak, U. (2025) · Biomedicines · doi:10.3390/biomedicines13102500 · Cited by 20
“Standard management involves supraphysiological doses of GCs to suppress adrenal androgen production; however, this approach is associated with an increased risk of obesity, hyperinsulinemia, and gestational diabetes [125].”
Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care
Balagamage, C., Arshad, A., Elhassan, Y., Said, W. B., Krone, R. E., Gleeson, H. K., & Idkowiak, J. (2023) · Clinical Endocrinology · doi:10.1111/cen.14992 · Cited by 19
Rosenberg, A. G. W., Pater, M. R. A., Pellikaan, K., Davidse, K., Kattentidt‐Mouravieva, A. A., Kersseboom, R., Bos‐Roubos, A. G., van Eeghen, A. M., Veen-Roelofs, J. M. C., van der Meulen, J. J., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225457 · Cited by 19
Characteristics of In2G Variant in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Kocova, M., Concolino, P., & Falhammar, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.788812 · Cited by 15
Clinical outcomes in 21-hydroxylase deficiency
Nordenström, A., Lajić, S., & Falhammar, H. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000625 · Cited by 15
Congenital adrenal hyperplasia due to 11-Beta-hydroxylase deficiency in a Tunisian family
Elfekih, H., Abdelkrim, A. B., Marzouk, H., Saad, G., Gribaa, M., Hasni, Y., & Maaroufi, A. (2020) · Pan African Medical Journal · doi:10.11604/pamj.2020.36.226.24270 · Cited by 15
“Patients with CAH were found to have a higher prevalence of metabolic and cardiovascular risk factors [8].”
BackgroundNokoff, N., Buchanan, C., & Barker, J. M. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae563 · Cited by 19
“In meta-analyses, individuals with CAH not only have increased risk of hypertension, but also insulin resistance and increased carotid intima thickness (48).”
Engberg, H., Nordenström, A., & Hirschberg, A. L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae696 · Cited by 16
Righi, B., Ali, S., Bryce, J., Tomlinson, J., Bonfig, W., Baronio, F., Costa, E. C., Guaragna‐Filho, G., T'Sjoen, G. G., Cools, M., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03330-w · Cited by 15
Impact of Glucocorticoids on Cardiovascular System—The Yin Yang Effect
Kelley, C., Molen, J. V., Choi, J., Bhai, S., Martin, K., Cochran, C., & Puthanveetil, P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111829 · Cited by 14
Charoensri, S., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad628 · Cited by 13
Lee, D. H., Kong, S. H., Jang, H. N., Ahn, C. H., Lim, S. G., Lee, Y. A., Kim, S. W., & Kim, J. H. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01090-0 · Cited by 11
Cardiovascular Risk Factors in Children and Adolescents with Congenital Adrenal Hyperplasia
Dehkordi, E. H., Khaheshi, S., Mostofizadeh, N., & Hashemipour, M. (2021) · Advanced Biomedical Research · doi:10.4103/abr.abr_219_20 · Cited by 13
Congenital adrenal hyperplasia: New biomarkers and adult treatments
Dreves, B., Reznik, Y., & Tabarin, A. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.01.008 · Cited by 15
Lim, S. G., Lee, Y. A., Jang, H. N., Kong, S. H., Ahn, C. H., Kim, S. W., Shin, C. H., & Kim, J. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.761258 · Cited by 13
Cardiometabolic Health in Adolescents and Young Adults with Congenital Adrenal Hyperplasia
Navardauskaitė, R., Semeniene, K., Šukys, M., Pridotkaite, A., Vanckavičienė, A., Žilaitienė, B., & Verkauskienė, R. (2022) · Medicina · doi:10.3390/medicina58040500 · Cited by 10
“In the recent systematic study with a large number of CAH patients cited above, no significant differences in total cholesterol, its fractions and triglycerides, were found compared to controls [6].”
BackgroundResultInfluentialTseretopoulou, X., Bryce, J., Chen, M., McMillan, M., Lucas-Herald, A. K., Ali, S., & Ahmed, S. F. (2023) · Clinical Endocrinology · doi:10.1111/cen.14961 · Cited by 13
Borges, J. H., de Oliveira, D. M., de Lemos‐Marini, S. H. V., Geloneze, B., Gonçalves, E. M., & Guerra‐Júnior, G. (2020) · Lipids · doi:10.1002/lipd.12280 · Cited by 12
Borges, J. H., Santoro, R. I., de Oliveira, D. M., de Lemos‐Marini, S. H. V., Geloneze, B., Guerra‐Júnior, G., & Gonçalves, E. M. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14233 · Cited by 8
Blood Pressure in Children with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Balagamage, C., Lawrence, N., Krone, R. E., Bacila, I. A., & Krone, N. P. (2023) · Hormone Research in Paediatrics · doi:10.1159/000533465 · Cited by 13
“Left ventricular dysfunction (LVD), endothelial dysfunction, and intimal thickening are known cardiovascular changes associated with CAH [20, 23, 35, 39, 40].”
Amr, N. H., Mahmoud, R. A. A., Youssef, O., Toaima, N. N., & Elsedfy, H. H. (2020) · Clinical Endocrinology · doi:10.1111/cen.14333 · Cited by 8
Impact of Adverse Gestational Milieu on Maternal Cardiovascular Health
Alkhatib, B., Salimi, S., Jabari, M., Padmanabhan, V., & Vyas, A. K. (2023) · Endocrinology · doi:10.1210/endocr/bqad060 · Cited by 8
Genotype and clinical outcomes in children with congenital adrenal hyperplasia
Yoon, J. Y., & Cheon, C. K. (2020) · Pediatrics International · doi:10.1111/ped.14478 · Cited by 8
Bancos, I., Kim, H., Cheng, H. K.-H., Rodríguez-Lee, M., Coope, H., Cicero, S., Goldsmith, H., Lin, V. H., & Jeha, G. S. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2450423 · Cited by 9
“…with GCs, even in the range commonly used to treat CAH, has been associated with a number of potentially serious health complications [11,13–25 ,72 Prolonged exposure to GCs in patients with CAH, especially at supraphysiologic doses, can exert growth-suppressing effects by interfering with…”
Self-citationSimeoli, C., de Angelis, C., Veneri, A. D., Menafra, D., Paola, N. D., Pivonello, C., Somma, C. D., Valerio, P., Melis, D., Alviggi, C., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.902844 · Cited by 7
“, 2010), and the GC treatment-related hypercortisolism, mimicking iatrogenic hypercortisolism (Tamhane et al., 2018), may predispose patients to the development of metabolic complications, since childhood to adulthood (Speiser et al.”
BackgroundAhmed, S. E. A. M., Soliman, A. T., Ramadan, M. A. E. F., Elawwa, A., Abugabal, A. M. S., Emam, M. H. A., & Sanctis, V. D. (2019) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v90i3.8732 · Cited by 14
Cardiovascular risk in Cuban adolescents and young adults with congenital adrenal hyperplasia
Reyes, T. M. E., Velepucha, A. K. P., Rego, J. O. C., Gómez, W. V., Alonso, E. D., & Falhammar, H. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01499-9 · Cited by 5
“The limited number of included patients with CAH, but still a decent size compared to previous studies [12, 26], the wide age range, only few males, not having access to the total glucocorticoid and androgen exposure during the entire life as well as the economic constraints preventing us from…”
BackgroundResultCongenital adrenal hyperplasia and hypertension
Tosun, B. G., & Güran, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00015-7 · Cited by 6
Challenges in managing disorders of sex development associated with adrenal dysfunction
Finkielstain, G. P., & Rey, R. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256393 · Cited by 6
“The most common cardiometabolic adverse outcomes in adults are obesity, hypertension, dyslipidemia, arteriosclerosis, and insulin resistance or type 2 diabetes [52].”
BackgroundZarić, S. P., Milenković, T., Todorovic, S., Mitrović, K., Cvetković, D., Cehic, M., Vekić, J., Dumic, K. K., & Vuković, R. (2025) · Metabolites · doi:10.3390/metabo15020089 · Cited by 7
“Studies show that CCAH adults suffer mostly from obesity, HTA, IR, and higher cIMT [8,11,40,41,43,54].”
Muscogiuri, G., Albertelli, M., Arnaldi, G., Barrea, L., Bellastella, G., Bonomi, M., Caputo, M., Caprio, M., Cignarelli, A., Gioia, L. D., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02862-y · Cited by 4
Langzeitmorbidität beim adrenogenitalen Syndrom
Tschaidse, L., Quitter, F., Hübner, A., & Reisch, N. (2022) · Der Internist · doi:10.1007/s00108-021-01223-6 · Cited by 4
Chen, L., Valentine, A., Davis, S., Graber, E., Fechner, P. Y., Furniss, A., Nahata, L., Pyle, L. L., Vyas, A. K., Vogiatzi, M. G., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae362 · Cited by 6
“Overall, there are conflicting data about the risk of dyslipidemia among individuals with CAH (29-31).”
Apsan, J., Lekarev, O., Thomas, C., Zhu, Y., Cohan, K., & Lin‐Su, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1433378 · Cited by 7
Takasawa, K., Nakamura‐Utsunomiya, A., Amano, N., Ishii, T., Hasegawa, T., Hasegawa, Y., Tajima, T., & Ida, S. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0292 · Cited by 5
Seagroves, A., Ross, H. M., Vidmar, A. P., Geffner, M. E., Kim, W. S., Hwang, D., Borzutzky, C., Fraga, N. R., & Kim, M. S. (2021) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2021.2020.0310 · Cited by 4
“These factors could lead to increased risk of cardiovascular disease, hypertension, and diabetes [2].”
BackgroundHubska, J., Kępczyńska‐Nyk, A., Czady-Jurszewicz, K., & Ambroziak, U. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020653 · Cited by 8
“It is believed that metabolic abnormalities in people with CAH are a consequence of the cortisol deficiency, with the subsequent androgen excess [58], hypercortisolism related to the GC treatment, which mimics iatrogenic hypercortisolism, as well as the underdevelopment of adrenal medulla [11,59,60].”
BackgroundCardiovascular Risk in Women With Nonclassical Congenital Adrenal Hyperplasia
Costa, F. C., Gomes, L. G., de Lima, T. M., Bortolotto, L. A., Costa‐Hong, V., Verardino, R. G. S., Rocha, M. D. S., Ueda, S. K. N., de Miranda, M. C., de Souza, H. P., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae155 · Cited by 3
Kyle, C. J., Boyle, L. D., Nixon, M., Homer, N. Z. M., Simpson, J., Rutter, A., Ramage, L. E., Kelman, A., Freel, E. M., Andrew, R., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae144 · Cited by 4
Hubska, J., Roszkowska, Z., Bobrowicz, M., Iwaniuk, S., Rak, B., & Ambroziak, U. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1581681 · Cited by 3
Auer, M. K., Paizoni, L., Nowotny, H. F., Lottspeich, C., Tschaidse, L., Schmidt, H., Bidlingmaier, M., & Reisch, N. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106271 · Cited by 3
Continuous Glucose Monitoring in Children and Adolescents with Congenital Adrenal Hyperplasia
Dubinski, I., Pozza, S. B., Debor, B., Nowotny, H. F., Reisch, N., Tschaidse, L., & Schmidt, H. (2023) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2023.2023-3-5 · Cited by 4
“However, reduced insulin sensitivity has been repeatedly shown in other studies (40,41,42,43).”
ResultAhn, C. H., Shim, J., Jang, H. N., Lee, Y. A., Lee, S., Choi, M. H., & Kim, J. H. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106374 · Cited by 4
A Broken Pathway: Understanding Congenital Adrenal Hyperplasia in the Newborn
Allis, K. (2021) · Neonatal Network The Journal of Neonatal Nursing · doi:10.1891/11-t-694 · Cited by 3
Hamidi, O., Auchus, R. J., Correa, R. R., Levine, A. C., Wierman, M. E., Hartzell, A. L., Lin, V. H., & Bancos, I. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag147 · Cited by 4
Self-citationTakasawa, K., & Kashimada, K. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.936944 · Cited by 2
Congenital Adrenal Hyperplasia in the Adolescent
Kim, M. S., Liang, M. C., Kokorowski, P. K., Tseng, T., Koppin, C. M., & Geffner, M. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-14881-1_59 · Cited by 2
Non-Classic Congenital Adrenal Hyperplasia in Childhood: A Review
Bertolucci, G., Tyutyusheva, N., Sepich, M., Baldinotti, F., Caligo, M. A., Sessa, M. R., Peroni, D. G., & Bertelloni, S. (2023) · Sexes · doi:10.3390/sexes4040030 · Cited by 1
Treatment and Follow-up of Non-stress Adrenal Insufficiency
Buğrul, F., & Murat, N. Ö. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2024-6-23-s · Cited by 5
“However, no significant difference was found in serum fasting blood glucose, insulin levels or lipid levels (3,29).”
Hormone replacement in disorders of sex development, and long-term effects
Nordenström, A., Mangone, A., & Mantovani, G. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102022 · Cited by 3
de Vries, L., Baum, M., Horovitz, M., Phillip, M., Barash, G., Pinhas‐Hamiel, O., & Lazar, L. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.08.005 · Cited by 3
Borges, J. H., Camargo, D. A., SEWAYBRICKER, L. E., Santoro, R. I., de Oliveira, D. M., de Lemos‐Marini, S. H. V., Geloneze, B., Guerra‐Júnior, G., & Gonçalves, E. M. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000504 · Cited by 3
Kara, Z., Demir, A. N., Sulu, C., Durcan, E., Uysal, S., Turan, H., Özkaya, H. M., Evliyaoğlu, S. O., Ercan, O., & Gönen, M. S. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0060 · Cited by 1
Complex metabolic–endocrine syndromes: associations with cardiovascular disease
Krentz, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00010-3 · Cited by 2
de Oliveira, D. M., Vasques, A. C. J., Gonçalves, E. M., de Lemos‐Marini, S. H. V., Guerra‐Júnior, G., & Geloneze, B. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0390 · Cited by 1
Neue Behandlungsstrategien bei adrenogenitalem Syndrom/21‑Hydroxylase-Mangel
Riedl, S. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00159-y · Cited by 1
Nationellt miljökvalitetsmål på lokal nivå
Engkvist, F. (2011)
Dhillo, W. S., Davies, M. C., Jayasena, C. N., & Seal, L. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198851899.003.0004
Delai, A. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2022.tde-06052022-161625 · Cited by 1
Congenital Adrenal Hyperplasia in the Adolescent
Kim, M. S., Liang, M. C., Kokorowski, P. K., Tseng, T., Koppin, C. M., & Geffner, M. E. (2022) · Springer eBooks · doi:10.1007/978-3-319-17002-2_59-2
Electrolyte Disturbance in Congenital Adrenal Hyperplasia Due to 21-OH Deficiency
Martinerie, L. (2023) · Endocrinology · doi:10.1007/978-3-030-44628-4_9-1
Electrolyte Disturbance in Congenital Adrenal Hyperplasia due to 21-OH Deficiency
Martinerie, L. (2023) · Endocrinology · doi:10.1007/978-3-031-27119-9_9
Metadata
- Authors
- Tamhane, S., Rodriguez-Gutierrez, R., Iqbal, A. M., Prokop, L. J., Bancos, I., Speiser, P. W., & Murad, M. H.
- Affiliations
- Mayo Clinic (US)
- Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
- Corresponding author
- Murad, Mohammad Hassan
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-09-28
- Volume
- 103
- Issue
- 11
- Pages
- 4097-4103
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2892833452
- Cited by
- 123
- References
- 46
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 14 · 2023: 22 · 2022: 23 · 2021: 17 · 2020: 9 · 2019: 7 · 2018: 1
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Endocrine Society (na)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- congenital adrenal hyperplasia, glucocorticoid therapy, cardiovascular risk factors, hypertension, insulin resistance, carotid intima-media thickness, metabolic risk factors, cortisol
- MeSH terms
- Adrenal Hyperplasia, Congenital, Blood Pressure, Cardiovascular Diseases, Cardiovascular System, Endocrinology, Glucocorticoids, Humans, Risk Factors, Prevalence, Practice Guidelines as Topic, Metabolic Syndrome, Carotid Intima-Media Thickness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.